Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Spevigo (spesolimab) for the treatment of patients with psoriasis
- Spevigo (spesolimab) for the treatment of patients with psoriasis
- Brukinsa (zanubrutinib) for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
- Keytruda (pembrolizumab) in combination with axitinib for the treatment of patients with renal cell carcinoma
- Diaflix (dapagliflozin) for the treatment of type 2 diabetes
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
